Table 3. HRs for associations between NUGs and MSS in CM patients of the MDACC study.
| NUGa | Frequency | Univariate analysis | Multivariate analysisb | |||
|---|---|---|---|---|---|---|
| All | Death (%) | HR (95% CI) | P | HR (95% CI) | P | |
| 0 | 413 | 31 (7.5) | 1.00 | 1.00 | ||
| 1 | 352 | 47 (13.4) | 1.92 (1.22-3.02) | 0.005 | 2.30 (1.43-3.68) | 0.001 |
| 2 | 93 | 17 (18.3) | 2.62 (1.45-4.73) | 0.001 | 3.02 (1.66-5.51) | <0.001 |
| Trend test | <0.001 | <0.001 | ||||
| 0 | 413 | 31 (7.5) | 1.00 | 1.00 | ||
| 1-2 | 445 | 64 (14.4) | 2.07 (1.35-3.17) | 0.001 | 2.47 (1.58-3.84) | <0.001 |
NUG: number of unfavorable genotype; MSS: melanoma-specific survival; CM: cutaneous melanoma; SNP:single nucleotide polymorphism; MDACC: The University of Texas M.D. Anderson Cancer Center; HR: hazards ratio; CI: confidence interval.
aNumber of risk genotypes were derived from rs2306574 CC+CT and rs6707820 TT+CT.
bMultivariate Cox regression analyses were adjusted for age, sex, Breslow thickness, regional/distant metastasis, ulceration, and mitotic rate of tumor.